NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)
Grant Opportunity Analysis
The National Institutes of Health (NIH) is offering a funding opportunity through the NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33), aimed at supporting investigator-initiated clinical trials focused on natural products such as botanicals and dietary supplements. This initiative seeks to encourage research that demonstrates a strong scientific premise for further testing, with the R61 phase providing up to three years of funding for milestone-driven studies assessing pharmacokinetics, bioavailability, and the effects of these products on specific target mechanisms. Successful projects may receive an additional three years of funding in the R33 phase to evaluate clinical outcomes related to target engagement. Interested applicants can submit proposals starting February 4, 2024, with a maximum project duration of five years, and should include a Plan for Enhancing Diverse Perspectives (PEDP) as part of their application. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and the award ceiling is set at $350,000.
Eligible Applicants
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.